Literature DB >> 10847561

An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease.

M A Pappolla1, Y J Chyan, B Poeggeler, B Frangione, G Wilson, J Ghiso, R J Reiter.   

Abstract

This review summarizes recent advancements in our understanding of the potential role of the amyloid beta protein in Alzheimer's disease. It also discusses the significance of amyloid beta in initiating the generation of partially reduced oxygen species and points out their role in damaging essential macromolecules in the CNS which leads to neuronal dysfunction and loss. Recently acquired experimental data links these destructive oxidative processes with some neurodegenerative aspects of Alzheimer's disease. The experimental findings related to the free radical scavenging and antioxidative properties of melatonin are tabulated and its efficacy and the likely mechanisms involved in its ability to reduce neuronal damage mediated by oxygen-based reactive species in experimental models of Alzheimer's disease are summarized. Besides the direct scavenging properties and indirect antioxidant actions of melatonin, its ability to protect neurons probably also stems from its antiamyloidogenic properties. Melatonin is also unique because of the ease with which it passes through the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10847561     DOI: 10.1007/s007020050018

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  46 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.

Authors:  Neeraj Joshi; Joyshree Biswas; C Nath; Sarika Singh
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

3.  Mass spectrometry-based screening for inhibitors of beta-amyloid protein aggregation.

Authors:  Xun Cheng; Richard B van Breemen
Journal:  Anal Chem       Date:  2005-11-01       Impact factor: 6.986

Review 4.  Aging, circadian rhythms and depressive disorders: a review.

Authors:  Inês Campos Costa; Hugo Nogueira Carvalho; Lia Fernandes
Journal:  Am J Neurodegener Dis       Date:  2013-11-29

Review 5.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

6.  Fluorine substituted methoxyphenylalkyl amides as potent melatonin receptor agonists.

Authors:  Andrew Tsotinis; Rodanthi Kompogennitaki; Ioannis Papanastasiou; Peter J Garratt; Alina Bocianowska; David Sugden
Journal:  Medchemcomm       Date:  2019-02-11       Impact factor: 3.597

7.  Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence.

Authors:  Michael J Jarzynka; Deepshikha K Passey; David A Johnson; Nagarjun V Konduru; Nicholas F Fitz; Nicholas M Radio; Mark Rasenick; Susan Benloucif; Melissa A Melan; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2008-10-28       Impact factor: 13.007

8.  Therapeutic application of melatonin in mild cognitive impairment.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

9.  Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease.

Authors:  Glenna A Dowling; Robert L Burr; Eus J W Van Someren; Erin M Hubbard; Jay S Luxenberg; Judy Mastick; Bruce A Cooper
Journal:  J Am Geriatr Soc       Date:  2007-12-07       Impact factor: 5.562

10.  Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders.

Authors:  Genaro G Ortiz; Gloria A Benítez-King; Sergio A Rosales-Corral; Fermín P Pacheco-Moisés; Irma E Velázquez-Brizuela
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.